Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

MLA

Hoechstetter, M. A., et al. “Early, Risk-Adapted Treatment with Fludarabine in Binet Stage A Chronic Lymphocytic Leukemia Patients: Results of the CLL1 Trial of the German CLL Study Group.” Leukemia, vol. 31, no. 12, Dec. 2017, pp. 2833–37. EBSCOhost, https://doi.org/10.1038/leu.2017.246.

APA

Hoechstetter, M. A., Busch, R., Eichhorst, B., Bühler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jäger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Müller, L., Goebeler, M., Wendtner, C. M., … Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31(12), 2833–2837. https://doi.org/10.1038/leu.2017.246

Chicago

Hoechstetter, M A, R Busch, B Eichhorst, A Bühler, D Winkler, M J Eckart, U Vehling-Kaiser, et al. 2017. “Early, Risk-Adapted Treatment with Fludarabine in Binet Stage A Chronic Lymphocytic Leukemia Patients: Results of the CLL1 Trial of the German CLL Study Group.” Leukemia 31 (12): 2833–37. doi:10.1038/leu.2017.246.